Table 5.
Clinicopathological characteristics of the patients included in the study.
| Variables | n = 100 |
|---|---|
| Epidemiological features | |
| Age at diagnosis [median, (range)] | 65.5 (21–90) |
| Age at diagnosis (%) | |
| <40 | 6 |
| 40–65 | 44 |
| >65 | 50 |
| Sex (%) | |
| Male | 53 |
| Female | 47 |
| Clinical melanoma features | |
| Anatomic site (%) | |
| Head/neck | 16 |
| Upper extremities | 16 |
| Trunk | 42 |
| Lower extremities | 18 |
| Acral | 8 |
| Sun related site (%) | |
| Non exposed | 21 |
| Occasionally exposed | 63 |
| Usually exposed | 16 |
| Pathological melanoma features | |
| Histological subtype (%) | |
| LMM | 10 |
| SSM | 68 |
| NM | 14 |
| AML | 8 |
| Breslow thickness (mean (±SD)) | 1.9 ± 2.1 |
| Breslow thickness (%) | |
| <1 mm | 47 |
| 1–2 mm | 21 |
| 2–4 mm | 19 |
| >4 mm | 13 |
| Ulceration (%) | |
| No | 74 |
| Yes | 26 |
| Regression (%) | |
| No | 52 |
| <50% | 41 |
| >50% | 7 |
| Mitoses/mm2 (%) | |
| <1 | 48 |
| >1 | 52 |
| Growth rate (%) | |
| SGM | 76 |
| FGM | 24 |
| Tumor stage (%) | |
| Localized (I–II) | 75 |
| Locoregional and metastatic disease (III–IV) | 25 |
| Months follow-up [median, (range)] | 32 (6–121) |
| Clinical outcome (%) | |
| Stable disease | 81 |
| Relapse (locoregional vs distant metastasis) | 8 |
| Exitus | 11 |